Please try another search
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. The company’s lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer’s disease, and degenerative conditions of the optic nerve. It was incorporated in 2002 and is based in Cottesloe, Australia.
Name | Age | Since | Title |
---|---|---|---|
Dao-Yi Yu | - | 2020 | Member of Scientific Advisory Board |
Anton Uvarov | - | 2017 | Non-Executive Director |
Christopher Ntoumenopoulos | 40 | 2023 | Non-Executive Chairman of the Board |
Anthony James Keating | - | 2023 | Non-Executive Director |
Allan Kermode | - | 2021 | Member of Scientific Advisory Board |
Clarke Barlow | 42 | 2023 | Director |
Peter Hnik | 67 | 2021 | Member of Scientific Advisory Board |
Frank W. Bonner | 70 | 2021 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review